Bioretec Hires Alan Donze as CEO

Bioretec has named Alan Donze as its new CEO, effective today.
 
Timo Lehtonen, who has led Bioretec as CEO since 2019, will become the company’s chief technology officer and lead development of its future product pipeline. This culminates the search for a new CEO for the company, which began in November 2023.
 
“It has been a privilege to lead Bioretec since 2019 and support its remarkable growth through interesting, challenging times. I am excited to focus my efforts on advancing the RemeOs product pipeline. Together with Alan, I am confident we will continue to strengthen our growth and transform bone fracture care. In my forthcoming role as CTO, I will leverage my extensive experience in innovation, product development, and regulatory expertise to support the management team and our skilled personnel. Our goal is to achieve the best possible outcomes in redefining bone fracture treatment and improving patients’ quality of life,” said Lehtonen.
 
Donze started his career in the banking industry, serving as VP of commercial lending and leveraged finance for a regional predecessor to Chase bank. He then left banking to begin his medical device career as a regional sales rep for Stryker Endoscopy in 1991.
 
Over his 13-year tenure at Stryker, Donze’s responsibilities grew to various senior management positions. These included VP and GM of Stryker Endoscopic Service and VP and GM of Stryker Communications. He also held senior leadership positions for other medical device and technology companies like Smith+Nephew, Bioventus, and Lima Corporate as well as venture-led startups like Isotis Orthobiologics, Aerobiotix, and Rx.Health.
 
“I am honored to be given the opportunity to lead Bioretec to the next level and deeply appreciate the confidence placed in me by the Board of Directors,” said Donze. “Bioretec’s groundbreaking work in developing alternatives to traditional metal implants represents a significant advancement in the medical field. Our products have the potential to reduce the need for invasive surgeries and improve patient outcomes, aligning with a critical need within the healthcare community. I am eager to contribute to Bioretec’s mission by expanding our efforts to introduce these transformative solutions to the benefit of many more patients. I look forward to the journey ahead and to our continued growth and success.”
 
In March, Bioretec announced it had received U.S. Food and Drug Administration (FDA) breakthrough status for its RemeOs spinal interbody cage implant.